XORTX regains Nasdaq compliance after reverse stock split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
XORTX Meets Nasdaq Continued Listing Requirements
April 21, 2026 7:00 AM EDTCALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has received a letter of compliance from the Nasdaq Stock Market LLCs ("Nasdaq) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires a listed companys shares to maintain a minimum bid price of US$1.00 per share (the Minimum Bid Requirement). In order to... More
